Hunting for the "Sweet Spot" in P2Y12 Receptor Blockade

Journal of the American College of Cardiology

Volumn 54, Issue 15, 2009, Pages 1447-1449

  Simon, Daniel I ^a   Parikh, Sahil A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

loading dose; platelet; STEMI; thienopyridine

Indexed keywords

CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; EDITORIAL; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; ST SEGMENT ELEVATION;

HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 70349665327     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.011     Document Type: Editorial

References (23)

1. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
2. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
3. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
4. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998) 1665-1671
5. Lau W.C., Gurbel P.A., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
6. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
7. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
8. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
9. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
10. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112 (2005) 2946-2950
11. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
12. Stanek E, Aubert R, Flockhart D, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco outcomes study. Paper presented at: Late Breaking Clinical Trial Session Society for Cardiovascular Angiography and Interventions 2009 Scientific Sessions; May 6, 2009; Las Vegas, NV.
13. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis In Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
14. Jakubowski J.A., Payne C.D., Brandt J.T., et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 47 (2006) 377-384
15. Kleiman N.S. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 138 (1999) 263-275
16. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
17. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
18. 12 antagonists. Semin Thromb Hemost 31 (2005) 195-204
19. Dangas G., Mehran R., Guagliumi G., et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 54 (2009) 1438-1446
20. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
21. Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009) 723-731
22. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
23. Goto S., Tamura N., Ishida H., and Ruggeri Z.M. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5′-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 47 (2006) 155-162